Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 5/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16205567 | 0.86 | MAP3K14 (0.37) | MAP3K14DYRK1AMAPKAPK2TLR7 | |
| SCHEMBL16205554 | 0.85 | MAP3K14 (0.36) | MAP3K14DYRK1AMAPKAPK2TLR7 | |
| SCHEMBL16205591 | 0.84 | MAP3K14 (0.36) | MAP3K14DYRK1AMAPKAPK2TLR7 | |
| SCHEMBL16205453 | 0.81 | MAP3K14 (0.39) | MAP3K14TLR7TLR9TLR8 | |
| SCHEMBL16205373 | 0.81 | MAP3K14 (0.43) | MAP3K14DYRK1AMAPKAPK2TLR7 | |
| SCHEMBL16205389 | 0.78 | TOP2A (0.30) | — | |
| SCHEMBL16205597 | 0.75 | RET (0.33) | — | |
| SCHEMBL16205612 | 0.75 | — | — | |
| SCHEMBL16205362 | 0.75 | PIK3CA (0.33) | — | |
| SCHEMBL16205695 | 0.75 | DYRK1A (0.49) | MAP3K14DYRK1AMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643964-B2 | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| US-9643964-B2 | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| US-20160075699-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-03-17 | — | — | US | disclosed |
| WO-2014174021-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075699-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | NFKBIA, IKBKG, MAP3K14 | MAP3K14 3/4885DYRK1A 1007/4885MAPKAPK2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.